A key pharmaceutical industry case argued just last week before the Supreme Court ended Monday morning with a loss for the industry. The Court announced it was divided 4-4 in the case Warner-Lambert v. Kent, a split that resulted from the recusal of Chief Justice John Roberts Jr. that deprived the Court of a ninth vote.
According to his financial disclosure form for 2006, Roberts owns between $15,001 and $50,000 in stock in Pfizer, the parent company of Warner-Lambert. The effect of a tie is that the lower court ruling, which went against Warner-Lambert, stands — though it does not create national precedent.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
